ActoGeniX: 20 million euros round


Ghent – The Belgian biopharma start-up ActoGeniX has closed a series A financing round in the volume of a20 million. The transaction was co-led by the two renowned VC investors Life Sciences Partners and GIMV. ActoGeniX has already announced a first closing of this transaction, raising a11.5 million. The company, which was founded in summer 2006, is developing a portfolio of novel therapeutic products addressing major diseases with unmet medical need, including gastrointestinal diseases, auto-immunity, allergy and metabolic diseases. ActoGeniX’ initial focus is on inflammatory bowel diseases and its lead product AG011 has been successfully tested in a clinical trial with Crohn’s disease patients. The company’s technology provides a solution to deliver active biologicals locally in the gastrointestinal tract, leading to a direct effect on target receptors present in the gut.



An industry based on renewable resources is not to be had for free. Switching from petroleum-driven large-scale industry to a biobased economy will cost both time and money. But the question is – who will pay for it? Can you...



Rotterdam – Dutch microarray diagnostics specialist Skyline Diagnostics BV has launched a unique microarray for subtyping patients with the most deadly blood cancer AML into different risk groups. AMLprofiler™ replaces current...



Leiden – Crucell N.V. has signed an agreement with Pepscan Therapeutics to use its protein mimicry technology to develop vaccines to treat undisclosed infectious diseases. Pepscan’s Chemical Linkage of Peptides onto Scaffolds...



Leiden/San Diego – Bad news for the Dutch Pharming Group and its partner Santarus Inc, who wants to market the heriditary angioedema treatment Rhucin (INN conestat alfa) in North America – the FDA said on Monday, that the...



Amsterdam – Dutch molecular diagnostics company Agendia NV has received the green light to use its MammaPrint breast cancer recurrence assay on Agilent microarray scanners and Agilent Bioanalyzers. The additional clearance will...



Leiden – Dutch OctoPlus N.V. has successfully completed an equity raising of EUR4m through a private placement of ordinary shares with new and existing investors, including a participation by its CEO elect, Jan Egberts. The...



Mechelen – Galapagos NV has completed first-in-human trials with its compound GLPG0555 in healthy volunteers as part of an arthritis alliance with Glaxo­SmithKline. The company also initiated Phase I testing for a second...



Rotterdam – Biopharmaceutical company arGEN-X BV has entered into an alliance that will generate monoclonal antibody candidates against diverse functional sites in targets from Eli Lilly and Co. Founded in 2008, the Dutch biotech...



Brussels – The European Biotechnology Network's "Biotechnology Funding Hub" service, which was launched last year, will be examining the US in this quarter, taking a close look at how companies can combine US and EC funding to...

Displaying results 51 to 60 out of 304

< Previous 51-60 Next >

© 2007-2015 BIOCOM


All videos

Product of the week



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...


All Events



BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes


  • CO.DON2.97 EUR2.41%
  • MOLOGEN5.06 EUR0.80%
  • CYTOS1.28 CHF0.79%


  • MEDIGENE12.90 EUR-11.03%
  • 4SC1.18 EUR-5.60%
  • PAION2.37 EUR-5.58%


  • 4SC1.18 EUR71.0%
  • MEDIGENE12.90 EUR63.9%
  • FORMYCON31.00 EUR31.1%


  • MORPHOSYS60.74 EUR-13.0%
  • BB BIOTECH281.20 EUR-11.2%
  • EPIGENOMICS5.31 EUR-10.6%


  • SANTHERA99.75 CHF2709.9%
  • CYTOS1.28 CHF652.9%
  • FORMYCON31.00 EUR336.6%


  • MOLOGEN5.06 EUR-53.1%
  • PAION2.37 EUR-22.3%
  • BIOFRONTERA2.57 EUR-21.2%

No liability assumed, Date: 18.04.2015

Current issue

All issues